Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee ...
Business Wire11d
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Progr…
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, ...
Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results
Reports record-high revenues since inceptionMONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty ...
Lands’ End Announces Fourth Quarter and Full Year Fiscal 2024 Results
Gross margin increased approximately 760 basis points compared to fiscal 2023All fourth quarter profitability measures improved ...
Morningstar12d
Franco-Nevada Reports Q4 and Year-end 2024 Results
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BOE Report9d
Saturn Oil & Gas Inc. Announces Record Q4 and Year End 2024 Results and Year End 2024 Reserves
Record 2024 exit volumes of 41,908 boe/d(2) and Q4/24 production of 41,051 boe/d (82% oil and liquids) Adjusted Funds Flow(1) ...